Brøgger A, Waksvik H, Thune P
Arch Dermatol Res. 1978 May 31;261(3):287-94. doi: 10.1007/BF00455298.
Five psoriasis patients treated with 8-methoxypsoralen and UVA (PUVA) were studied by lymphocyte cultures at the 1st, 5th, 10th and 20th treatment and at a maintenance treatment 6 months later. Abnormal amounts of chromosome aberrations were not found, and the frequency of sister chromatid exchange (examined at the last treatment) was not increased. In vitro experiments with nanogram doses of psoralen (similar to plasma levels in patients) showed no increase in chromosome aberration or SCE freqency. The results indicate that therapeutic doses of PUVA have no clastogenic effect.
对5名接受8-甲氧基补骨脂素和紫外线A（PUVA）治疗的银屑病患者，在第1次、第5次、第10次和第20次治疗时以及6个月后的维持治疗时进行淋巴细胞培养研究。未发现染色体畸变数量异常，且（在最后一次治疗时检测的）姐妹染色单体交换频率未增加。用纳克剂量的补骨脂素进行的体外实验（类似于患者血浆水平）显示染色体畸变或SCE频率没有增加。结果表明，治疗剂量的PUVA没有致断裂作用。
